TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31037611

Group type: EXPERIMENTAL
Intervention: Chiglitazar 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 32 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 24 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 48 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 72 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar 16 mg (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiglitazar (overall)
Number of subjects: 0
Study: 28159358

Group type: EXPERIMENTAL
Intervention: Supervised centre-based exercise rehabilitation
Number of subjects: 158

Group type: COMPARATOR
Intervention: Self-management home-based exercise rehabilitation
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Home-based setting preference
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Depression score in Hospital Anxiety and Depression Score
Number of subjects: 158
Study: 26509793

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) for 12 weeks (n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Lactobacillus casei Shirota (no LcS) (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls (n = 16)
Number of subjects: 28
Study: 23389073

Group type: EXPERIMENTAL
Intervention: Mobile Simulation Unit (MSU) training on LapSim
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Mobile Simulation Unit (MSU) training on FLS
Number of subjects: 144

Group type: COMPARATOR
Intervention: Fixed-site training on LapSim
Number of subjects: 144

Group type: COMPARATOR
Intervention: Fixed-site training on FLS
Number of subjects: 144
Study: 21691610

Group type: EXPERIMENTAL
Intervention: Non-platform-switched implants
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Implant platform 4.3 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Implant platform 4.8 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Implant platform 5.5 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Correlation with biglycans
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Correlation with tumor necrosis factor-a
Number of subjects: 9
Study: 17585313

Group type: EXPERIMENTAL
Intervention: pegaptanib sodium (0.3, 1, and 3 mg)
Number of subjects: 569

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 569
Study: 16939029

Group type: EXPERIMENTAL
Intervention: Total Etch + Syntac Single Component
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Syntac Single Component
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 3
Study: 12904090

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study: 10714832

Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (ATC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV) with immediate pressure rise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV) with delayed pressure rise
Number of subjects: 10
Study: 9185468

Group type: EXPERIMENTAL
Intervention: Preoperative 50 mg flurbiprofen with standardized general anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standardized general anesthesia (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional combined epidural and general anesthesia with epidural administration of 0.25% bupivacaine 5‐8 ml and 0.1‐0.2 mg buprenorphine after surgery
Number of subjects: 60
Study: 1489039

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dorsal nerve block
Number of subjects: 0
Study: 3516409

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29722747

Group type: EXPERIMENTAL
Intervention: Cyclic natural progesterone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27942208

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 µg)/salbutamol (2.5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 24297940

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7)
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Standard-dose cytarabine (100 mg/m2 per day by continuous infusion for 10 days)
Number of subjects: 1942
Study: 22735285

Group type: EXPERIMENTAL
Intervention: Absorbable pin fixation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No fixation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soft cast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative angles over 30 degrees
Number of subjects: 100
Study: 21395141

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation with 0.2% Prismocitrate 10/2 solution
Number of subjects: 38
Study: 17478491

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g i.v.) for 4 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (2 g i.v.) for 4 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo (first 4 months) followed by L-carnitine (2 g i.v.) for 4 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-carnitine (0.5 mM and 5 mM) pre-incubation before agonist stimulation
Number of subjects: 10
Study: 16214622

Group type: EXPERIMENTAL
Intervention: 3-dimensional facial scanning technique using Minolta Vivid 900 laser-scanning devices
Number of subjects: 40
Study: 11859207

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and TME
Number of subjects: 656

Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Margins <= 1 mm
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Margins <= 2 mm
Number of subjects: 656
Study: 10550151

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with ifosfamide 10 g/m², carboplatin 1200 mg/m², and etoposide 1200 mg/m² (ICE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with ifosfamide, carboplatin, and etoposide (ICE)
Number of subjects: 69
Study: 7598070

Group type: EXPERIMENTAL
Intervention: Eggs from hens fed 10% ground flaxseed
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Eggs from hens fed 20% ground flaxseed
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (0% ground flaxseed)
Number of subjects: 28
Study: 2358236

Group type: EXPERIMENTAL
Intervention: Physical activity program (15 minutes of regular physical exercise before lunch, 5 days a week)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Social games (control group, seated activities for the same time periods)
Number of subjects: 540
Study: 65818

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone-caproate (Primostat)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone-caproate
Number of subjects: 39
Study: 31266529

Group type: EXPERIMENTAL
Intervention: WI plus L-TAP
Number of subjects: 108

Group type: COMPARATOR
Intervention: WI
Number of subjects: 108
Study: 27988484

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 380
Study: 27505900

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary, client-centered fall prevention program
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study: 23585744

Group type: EXPERIMENTAL
Intervention: auto-titrating continuous positive airway pressure (auto-CPAP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: mandibular advancement device (MAD) + nasal strip
Number of subjects: 24

Group type: COMPARATOR
Intervention: auto-CPAP and MAD + nasal strip
Number of subjects: 24
Study: 22201238

Group type: EXPERIMENTAL
Intervention: Enhanced Parents Matter! Program
Number of subjects: 1115
Study: 19477655

Group type: EXPERIMENTAL
Intervention: Alar cinch suture combined with muco‐musculo‐periosteal V‐Y closure (ACVY)
Number of subjects: 22
Study: 17825689

Group type: EXPERIMENTAL
Intervention: Titration group: 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nontitration group: 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Titration group
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nontitration group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 15278855

Group type: EXPERIMENTAL
Intervention: Orofacial injury patients
Number of subjects: 336

Group type: COMPARATOR
Intervention: Elective surgery patients (control)
Number of subjects: 336
Study: 11176729

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (35.0 or 32.5 mg OD)
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose lisinopril (5.0 or 2.5 mg OD)
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose lisinopril
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: High-dose strategy
Number of subjects: 3164
Study: 9506648

Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GH plus OX
Number of subjects: 70

Group type: COMPARATOR
Intervention: Historical control (no treatment)
Number of subjects: 70
Study: 8155435

Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen 200 mg followed by 12.5 mg h‐1 over 13 h
Number of subjects: 32

Group type: COMPARATOR
Intervention: extradural morphine 4 mg
Number of subjects: 32
Study: 3247565

Group type: EXPERIMENTAL
Intervention: Local injections of purified botulinum toxin type 'A'
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline solution injected with the same method as botulinum toxin
Number of subjects: 4
Study: 31218661

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tildrakizumab (after switching from etanercept)
Number of subjects: 0
Study: 29698447

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Celecoxib (absent aspirin)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 27914515

Group type: EXPERIMENTAL
Intervention: EPA (Eicosapentaenoic Acid)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25424785

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control
Number of subjects: 980
Study: 23719550

Group type: EXPERIMENTAL
Intervention: Moderate-protein weight-loss diet
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard-protein weight-loss diet
Number of subjects: 76
Study: 20521975

Group type: EXPERIMENTAL
Intervention: Red ginseng extract powder (1 g) administered orally per week for 3 years
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Red ginseng extract powder (1 g) administered orally per week for 3 years (male subgroup)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 643
Study: 17457338

Group type: COMPARATOR
Intervention: 0 g alcohol (control)
Number of subjects: 51
Study: 15812447

Group type: EXPERIMENTAL
Intervention: Algal-DHA
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Fish-DHA
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control
Number of subjects: 361
Study: 12428041

Group type: EXPERIMENTAL
Intervention: Phenobarbitone 10mg/kg given within 6 hours of life followed by 5mg/kg/day till day 5 of life intravenously
Number of subjects: 150

Group type: COMPARATOR
Intervention: Phenobarbitone 5mg/kg for 5 days
Number of subjects: 150
Study: 10500973

Group type: EXPERIMENTAL
Intervention: Hemostatic puncture closing device
Number of subjects: 240

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 240
Study: 8942463

Group type: EXPERIMENTAL
Intervention: D-cycloserine at 50 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1653594

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg, increased to 80 mg if needed after 4 weeks
Number of subjects: 490

Group type: COMPARATOR
Intervention: Atenolol 50 mg, increased to 200 mg if needed after 4 weeks
Number of subjects: 490
Study: 6354603

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment plus nimesulide (100 mg twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Antibiotic treatment plus placebo
Number of subjects: 45
Study: 31280114

Group type: EXPERIMENTAL
Intervention: Music (piano training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video (visuospatially demanding video game)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study: 29846553

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5084

Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 5084
Study: 27383413

Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL) ovarian drilling
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian drilling (LOD)
Number of subjects: 246
Study: 24170718

Group type: EXPERIMENTAL
Intervention: Managing Cancer And Living Meaningfully (CALM) psychotherapy
Number of subjects: 50
Study: 22264664

Group type: EXPERIMENTAL
Intervention: O(2)/N(2)O
Number of subjects: 72

Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 72
Study: 20961784

Group type: EXPERIMENTAL
Intervention: Pre-antiretroviral therapy
Number of subjects: 1571
Study: 17326029

Group type: EXPERIMENTAL
Intervention: Povidone-iodine scrub
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alcohol wash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waterless alcohol-chlorhexidine lotion
Number of subjects: 60
Study: 16303295

Group type: EXPERIMENTAL
Intervention: formoterol 24 microg (2 x 12 microg via Aerolizer)
Number of subjects: 17

Group type: COMPARATOR
Intervention: salbutamol 600 microg (6 x 100 microg via metered-dose inhaler)
Number of subjects: 17
Study: 14557355

Group type: EXPERIMENTAL
Intervention: Segmental ostial catheter ablation (SOCA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Left atrial catheter ablation (LACA)
Number of subjects: 80
Study: 11218985

Group type: EXPERIMENTAL
Intervention: 40 U of intranasal elcatonin (ELC) 2 months ON, 1 month OFF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study: 8881638

Group type: COMPARATOR
Intervention: Nitrous oxide at 0% concentration
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% concentration
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% concentration
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% concentration
Number of subjects: 88
Study: 1315646

Group type: EXPERIMENTAL
Intervention: Phentolamine (500 micrograms/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adrenaline infusion
Number of subjects: 10
Study: 6384285

Group type: EXPERIMENTAL
Intervention: Selenium sulfide (2.5%) lotion applied daily for 10 minutes for 7 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 31199744

Group type: EXPERIMENTAL
Intervention: MTA placement over cotton in the pulp chamber and canal orifices (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTA with RMGI over it (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTA in canal orifices with RMGI over MTA and pulp chamber floor (Group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTA in canal orifices with RMGI over MTA but not on pulpal floor (Group 4)
Number of subjects: 40
Study: 30241682

Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 22

Group type: COMPARATOR
Intervention: ProRoot MTA
Number of subjects: 22
Study: 27329037

Group type: EXPERIMENTAL
Intervention: 70g dark chocolate (150 mg epicatechin) with placebo capsules
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pure epicatechin capsules (2 × 50 mg epicatechin) with 75g white chocolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo capsules with 75g white chocolate (0 mg epicatechin)
Number of subjects: 20
Study: 24074291

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01% combined with fluorometholone 0.1%
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01% combined with ketorolac 0.4%
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22607938

Group type: EXPERIMENTAL
Intervention: Topical ophthalmic tofacitinib 0.005% QD
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Topical ophthalmic tofacitinib 0.003% BID
Number of subjects: 82

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 82
Study: 21404880

Group type: EXPERIMENTAL
Intervention: Integrated intervention
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 385
Study: 17031690

Group type: EXPERIMENTAL
Intervention: Intensified cytarabine and idarubicin followed by interferon alfa (IFN-alpha) maintenance
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-dose cytarabine and IFN-alpha
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intensified cytarabine and idarubicin followed by IFN-alpha maintenance
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 118
Study: 16194178

Group type: EXPERIMENTAL
Intervention: Co-ordinated care post-discharge intervention (telephone liaison by Registered Nurse at 2, 6, and 12 weeks)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no postoperative telephone contact from Registered Nurse)
Number of subjects: 133
Study: 11816046

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combination of both agents
Number of subjects: 52
Study: 10519718

Group type: EXPERIMENTAL
Intervention: Standardised training programme and dietary advice (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dietary advice alone (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (after one year reassessment)
Number of subjects: 30
Study: 7733022

Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1936833

Group type: EXPERIMENTAL
Intervention: senna/PEG‐ELS
Number of subjects: 120

Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 120
Study: 6128740

Group type: EXPERIMENTAL
Intervention: 5 mg lorazepam orally 1 hour before induction of labour
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no pre-induction medication)
Number of subjects: 38
Study: 31850844

Group type: EXPERIMENTAL
Intervention: Methylphenidate (catecholamine transporter blocker)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 29230987

Group type: EXPERIMENTAL
Intervention: Depression patients (study group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Schizophrenics with homicide behavior (control group)
Number of subjects: 90
Study: 27884840

Group type: EXPERIMENTAL
Intervention: Teacher training, provision of lesson and child-parent interactive homework plans and teaching materials
Number of subjects: 2221
Study: 25483480

Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 274

Group type: COMPARATOR
Intervention: SA14-14-2
Number of subjects: 274
Study: 22344062

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stretching with motor control exercises for the hip and trunk
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Core endurance with motor control exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 19632053

Group type: EXPERIMENTAL
Intervention: Computerized gender-specific, parent-involvement intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 17636179

Group type: EXPERIMENTAL
Intervention: Iloprost (n = 21, group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tramadol (n = 20, group 2)
Number of subjects: 41
Study: 15770970

Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin in ASH
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tc‐99m tetrofosmin in normal controls
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of washout rates between ASH and normal controls
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tc‐99m tetrofosmin in NYHA II-III patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation of washout with interventricular septum and posterior wall thickness
Number of subjects: 28
Study: 11996469

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.5 mg/m2 on days 2-5
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on day 1 and topotecan 1.25 mg/m2 on days 2-5
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin and topotecan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 and topotecan 1.25 mg/m2
Number of subjects: 18
Study: 9657583

Group type: EXPERIMENTAL
Intervention: Bennett valve
Number of subjects: 10

Group type: COMPARATOR
Intervention: Peters valve
Number of subjects: 10
Study: 7863934

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg of gadopentetate dimeglumine at 0.5 T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg of gadopentetate dimeglumine at 1.5 T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg of gadodiamide at 0.5 T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg of gadodiamide at 1.5 T
Number of subjects: 0
Study: 2592097

Group type: EXPERIMENTAL
Intervention: Metal staples
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 200